Organisation paid for research Program year 2025 Source: CMS Open Payments

Reid Physician Associates

Neither a doctor nor a teaching hospital

Research payments

$319,749

56 payments

Through program year 2025, Reid Physician Associates is reported as receiving $319,749 in research payments, across 56 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $57,189 6
2024 Research $64,459 8
2023 Research $76,303 10
2022 Research $50,953 11
2021 Research $29,483 6
2020 Research $20,825 3
2019 Research $20,538 12

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amgen Inc. $119,502 11 payments
  2. Merck Sharp & Dohme Corporation $85,659 23 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $71,960 14 payments
  4. Abbott Laboratories $22,821 3 payments
  5. Pfizer Inc. $12,180 2 payments
  6. Novo Nordisk AS $7,628 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction $73,917 12 payments
  2. Bmad $57,460 12 payments
  3. ACS-REAL Pragmatic study (EVOLVE MI) $34,138 1 payment
  4. A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) $27,261 1 payment
  5. Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9i (cvMOBIUS) $26,445 4 payments
  6. OCEANa-Outcomes P3 CV $23,014 2 payments
  7. Eclipse $18,432 2 payments
  8. Heart Sounds Registry in Patients Using the Wearable Cardioverter Defibrillator $14,500 2 payments
  9. A Phase 2 Randomized Doubleblind Placebocontrolled Study to Evaluate the Efficacy and Safety of An Oral Branchedchain Ketoacid Dehydrogenase Kinase Inhibitor Pf07328948 in Adults With Heart Failure Branchhf $12,180 2 payments
  10. A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction $9,108 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record